KR20010101074A - 17-케토스테로이드 화합물 및 그의 유도체, 대사산물 및전구체의 간염 ｃ 바이러스 및 기타 토가바이러스 치료용용도 - Google Patents
17-케토스테로이드 화합물 및 그의 유도체, 대사산물 및전구체의 간염 ｃ 바이러스 및 기타 토가바이러스 치료용용도 Download PDFInfo
- Publication number
- KR20010101074A KR20010101074A KR1020017006525A KR20017006525A KR20010101074A KR 20010101074 A KR20010101074 A KR 20010101074A KR 1020017006525 A KR1020017006525 A KR 1020017006525A KR 20017006525 A KR20017006525 A KR 20017006525A KR 20010101074 A KR20010101074 A KR 20010101074A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- alkyl
- virus
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10992498P | 1998-11-24 | 1998-11-24 | |
| US60/109,924 | 1998-11-24 | ||
| US12408799P | 1999-03-11 | 1999-03-11 | |
| US60/124,087 | 1999-03-11 | ||
| US12605699P | 1999-03-23 | 1999-03-23 | |
| US60/126,056 | 1999-11-08 | ||
| PCT/US1999/028082 WO2000032177A2 (en) | 1998-11-24 | 1999-11-24 | Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010101074A true KR20010101074A (ko) | 2001-11-14 |
Family
ID=27380740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017006525A KR20010101074A (ko) | 1998-11-24 | 1999-11-24 | 17-케토스테로이드 화합물 및 그의 유도체, 대사산물 및전구체의 간염 ｃ 바이러스 및 기타 토가바이러스 치료용용도 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1133287A2 (pt) |
| JP (1) | JP2002531397A (pt) |
| KR (1) | KR20010101074A (pt) |
| CN (1) | CN1328463A (pt) |
| AP (1) | AP2001002181A0 (pt) |
| AU (1) | AU775614B2 (pt) |
| BR (1) | BR9915644A (pt) |
| CA (1) | CA2352205A1 (pt) |
| HK (1) | HK1042426A1 (pt) |
| ID (1) | ID29864A (pt) |
| IL (2) | IL142942A0 (pt) |
| NZ (1) | NZ511721A (pt) |
| OA (1) | OA11716A (pt) |
| WO (1) | WO2000032177A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US6555523B1 (en) | 1999-07-08 | 2003-04-29 | Patrick T. Prendergast | Use of cirsiliol and derivatives to treat infections |
| DK1955700T3 (da) | 1999-09-30 | 2011-05-23 | Harbor Biosciences Inc | Terapeutisk behandling af androgenreceptor-betingede lidelser |
| EP1534299A4 (en) * | 2002-07-02 | 2007-04-11 | Corcept Therapeutics Inc | METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY |
| CA2496867A1 (en) * | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| PL2219642T3 (pl) | 2007-11-15 | 2012-02-29 | Madaus Gmbh | Komponent sylibininy do leczenia zapalenia wątroby |
| CN102993148B (zh) * | 2011-09-13 | 2015-12-09 | 复旦大学 | 槲皮素衍生物或其类似物及其应用 |
| WO2013178782A1 (en) * | 2012-05-30 | 2013-12-05 | Universidad De Zaragoza | Allosteric inhibitors of ns3 protease from hepatitis c virus |
| CN108003212A (zh) * | 2017-12-24 | 2018-05-08 | 扬州工业职业技术学院 | 一种去氢表雄酮-6-葡萄糖苷衍生物及其作为抗丙型肝炎病毒药物的应用 |
| CN110452280B (zh) * | 2019-07-25 | 2020-11-17 | 中国人民解放军第二军医大学 | 一类四环三萜酸衍生物及其制备方法与应用 |
| JP2023543352A (ja) * | 2020-09-22 | 2023-10-13 | マイクロナイゼーション テクノロジーズ アンド セラピューティクス グループ エルエルシー | 噴霧器および噴霧化された抗ウイルス薬 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194728C (nl) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan. |
| US5837269A (en) * | 1989-09-25 | 1998-11-17 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
| CN1216470A (zh) * | 1996-04-17 | 1999-05-12 | 帕特里克·T·普伦德加斯特 | 脱氢表雄酮组合治疗方法 |
| AU5221998A (en) * | 1997-04-17 | 1998-11-13 | Patrick T. Prendergast | Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors |
-
1999
- 1999-11-24 BR BR9915644-0A patent/BR9915644A/pt not_active Application Discontinuation
- 1999-11-24 NZ NZ511721A patent/NZ511721A/en unknown
- 1999-11-24 OA OA1200100128A patent/OA11716A/en unknown
- 1999-11-24 AU AU31052/00A patent/AU775614B2/en not_active Ceased
- 1999-11-24 KR KR1020017006525A patent/KR20010101074A/ko not_active Application Discontinuation
- 1999-11-24 JP JP2000584873A patent/JP2002531397A/ja active Pending
- 1999-11-24 EP EP99965050A patent/EP1133287A2/en not_active Withdrawn
- 1999-11-24 WO PCT/US1999/028082 patent/WO2000032177A2/en not_active Application Discontinuation
- 1999-11-24 IL IL14294299A patent/IL142942A0/xx active IP Right Grant
- 1999-11-24 ID IDW00200101129A patent/ID29864A/id unknown
- 1999-11-24 AP APAP/P/2001/002181A patent/AP2001002181A0/en unknown
- 1999-11-24 CN CN99813658A patent/CN1328463A/zh active Pending
- 1999-11-24 CA CA002352205A patent/CA2352205A1/en not_active Abandoned
-
2001
- 2001-05-03 IL IL142942A patent/IL142942A/en not_active IP Right Cessation
-
2002
- 2002-03-25 HK HK02102267.0A patent/HK1042426A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL142942A (en) | 2006-08-20 |
| WO2000032177A2 (en) | 2000-06-08 |
| BR9915644A (pt) | 2001-08-07 |
| AU3105200A (en) | 2000-06-19 |
| CA2352205A1 (en) | 2000-06-08 |
| HK1042426A1 (zh) | 2002-08-16 |
| OA11716A (en) | 2005-01-25 |
| EP1133287A2 (en) | 2001-09-19 |
| AU775614B2 (en) | 2004-08-05 |
| NZ511721A (en) | 2004-07-30 |
| ID29864A (id) | 2001-10-18 |
| IL142942A0 (en) | 2002-04-21 |
| JP2002531397A (ja) | 2002-09-24 |
| WO2000032177A3 (en) | 2001-03-22 |
| CN1328463A (zh) | 2001-12-26 |
| AP2001002181A0 (en) | 2001-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008255138B2 (en) | Therapeutic treatments for blood cell deficiencies | |
| US20040220161A1 (en) | Pharmaceutical compositions and treatment methods-6 | |
| KR20010101074A (ko) | 17-케토스테로이드 화합물 및 그의 유도체, 대사산물 및전구체의 간염 ｃ 바이러스 및 기타 토가바이러스 치료용용도 | |
| WO2002069977A1 (en) | Use of certain steroids for treatment of blood cell deficiencies | |
| AU2002244247A1 (en) | Use of certain steroids for treatment of blood cell deficiencies | |
| RU2295534C2 (ru) | Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений | |
| AU2004237812B2 (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis | |
| AU2005211675B2 (en) | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | |
| EP1422234A2 (en) | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | |
| MXPA01005170A (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses | |
| WO2000032176A2 (en) | Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis | |
| MXPA01005166A (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis | |
| ZA200103845B (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis. | |
| ZA200106980B (en) | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.[bromoepiandrosterone. | |
| MXPA01009624A (en) | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |